SUPN May 2024 34.000 put
| Previous close | 1.8500 |
| Open | 1.8500 |
| Bid | 4.7000 |
| Ask | 6.5000 |
| Strike | 34.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.8500 - 1.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | 50 |
PR NewswireM8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ('Supernus'), a biopharmaceutical company focused on the development and commercialization of products for the treatment of diseases of the central nervous system (CNS), to seek regulatory approval and commercialize Qelbree® (Viloxazine XR) under M8's trademark in Latin America.
ZacksAhead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Supernus (SUPN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
GlobeNewswireBusy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree®The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two years (2020-2022)1Although symptoms are present in childhood, a significant portion of women with ADHD don’t receive a diagnosis until they are adults2 ROCKVILLE, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mother of two, Busy Philipps is teaming up with Supernus
